335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29645 | Thierry Gil | sarcome | Boehringer Ingelheim | Brightline-1 | Trial closed for recruitment | A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma (Brightline-1 ; 1403-0008) | thierry.gil@hubruxelles.be | 2/3 | 2 | ||
| 22827 | TNBC | Daphné t'Kint de Roodenbeke | Breast | UZ-Brussel | BSMO 2014 01 | Trial closed | A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negative breast cancer | daphne.tkint@hubruxelles.be | 2 | 2 | |
| 29172 | Nuria Kotecki | Multiple | Bicycle Tx Limited | BT5528-100 | Trial open for recruitment | Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | ||
| 29196 | Nuria Kotecki | Multiple | Byondis | BYON3521.001 | Trial closed for recruitment | A first-in-human dose-escalation and expansion study with the antibodydrug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-MET expressing locally advanced or metastatic solid tumours (BYON3521.001) | Nuria.Kotecki@hubruxelles.be | 1 | 1 | ||
| 22766 | Any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Gamamabs Pharma | C101 | Trial closed | Open, non-controlled, multicenter, first-in-human study for the evaluation of the safety, pharmacokinetics and preliminary antitumor activity of GM102 in patients with advanced pretreated gynecological cancer | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22703 | Stage III or IV, unresecable | Joseph Kerger | Skin | BMS - Bristol Myers Squibb int. | CA045-001 | Trial closed | A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma | joseph.kerger@hubruxelles.be | 3 | 3 | |
| 22707 | Complete resection | Joseph Kerger | Skin | BMS - Bristol Myers Squibb int. | CA209-8RX | Trial open for recruitment | A national, prospective, Therapeutic Non-Interventional Clinical Trial (TNICT) in patients receiving adjuvant nivolumab therapy for resected melanoma | joseph.kerger@hubruxelles.be | 4 | 4 | |
| 22758 | ECOG 0 or 1 | Ahmad Hussein Awada | Multiple | BMS - Bristol Myers Squibb int. | CA209358 | Trial closed | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 29426 | 1.Male or female patients ? 18 years of age. 2.Patients with CML-CP within 3 months of diagnosis* 3.Diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations (presence of BCR-ABL1 in a review of a minimum 20 m |
Adriano Salaroli | LMC | Novartis | CABL001J12301 | Trial open for recruitment | A Phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | adriano.salaroli@hubruxelles.be | 3 | 3 | |
| 28451 | Alain Hendlisz | Colon | Novartis | CADPT01C12101 | Trial closed | A Phase Ib multicenter, open-label dose escalation and expansion platform study of selected drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer | alain.hendlisz@hubruxelles.be | 1/1b | 1 | ||
| 29418 | Stage Mayo IIIb | Nathalie Meuleman | Amyloidose | Caelum Biosciences, Inc. | CAEL101-301 | Trial closed for recruitment | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment- Naïve Patients with Mayo Stage IIIb AL Amyloidosis | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 29419 | Mayo stage IIIa | Nathalie Meuleman | Amyloidose | Caelum Biosciences, Inc. | CAEL101-302 | Trial closed for recruitment | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 22651 | Metastatic | Christiane Jungels | Multiple | Cantargia AB | CANFOUR | Trial closed | An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |
| 29061 | Bogdan Grigoriu | Lung | Novartis | CANOPY-N | Trial closed | A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) | Bogdan.Grigoriu@hubruxelles.be | 2 | 2 |